Wegovy to play key role in UK obesity pilot scheme, says analyst
The UK has recently announced a two-year pilot scheme aimed at tackling obesity, which has become a significant financial burden on the National Health Service (NHS).
With a budget of £40 million ($50 million) over two years, the program aims to reduce patient wait times for effective obesity drugs by enabling access through general practitioners and specialist pharmacies. While these measures are crucial for addressing the obesity crisis, long-term weight management support is also necessary, says data and analytics company GlobalData.
GlobalData’s recent report, “ Obesity: Seven-Market Drug Forecast and Market Analysis,” forecasts the UK obesity market to grow from $2.43 billion in 2021 to $37.06 billion in 2031. Forecasted drugs include Danish firm Novo Nordisk’s (NOV: N) Wegovy (semaglutide), which is set to be a top-selling drug by the end of the forecast period.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
Free
7 day trial access
- All the news that moves the needle in pharma and biotech
- Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
- Receive The Pharma Letter daily news bulletin, free forever.
Become a subscriber
£820
Or £77 per month
- Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
- Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
- Daily roundup of key events in pharma and biotech.
- Monthly in-depth briefings on Boardroom appointments and M&A news.
- Choose from a cost-effective annual package or a flexible monthly subscription
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
More on this story...
Today's issue
Company Spotlight
More Features in Pharmaceutical
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze